Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Organigram Global and Aurora Cannabis signed an arrangement agreement on November 2, 2026 (announced November 3) for Organigram to buy all Aurora shares through a court-approved plan of arrangement. Aurora holders can choose C$7.80 per share in cash, shares, or a mix, subject to proration. Funding includes a C$187.5M private placement from British American Tobacco's subsidiary and up to C$210M in ATB senior secured credit facilities. Aurora can still consider a superior proposal, which may include Curaleaf's existing hostile bid if its terms change, and both sides have termination and reverse-termination fees.
Company's press release (SEC filing): Organigram Global Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq
